National Center for Construction Safety and Health Research and Translation (U54) vs Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Side-by-side comparison of two grants.
| Attribute | National Center for Construction Safety and Health Research and Translation (U54) | Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) |
|---|---|---|
| Type | Grant | Grant |
| Funding amount | $5.8M | — |
| Deadline | Closes 2026-12-01 | Closes 2026-11-19 |
| Region | US | US |
| Sector | Health | Health |
| Funder | Centers for Disease Control and Prevention - ERA | National Institutes of Health |
| Who it's for | nonprofits, researchers, students | individuals, researchers, government |